trazodone and Sleep Wake Disorders studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.

Research Excerpts

Excerpt	Relevance	Reference
"There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD)."	9.19	Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. ( Camargos, EF; Louzada, FM; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2014)
"Despite its frequent use as a hypnotic, trazodone has not been systematically assessed in fibromyalgia patients."	9.14	Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2010)
"The evaluation of therapeutic efficiency and safety of using trazodone in treatment of adjustment disorders with the particular focus on dominant symptoms in this illness that is anxiety, lowering of the mood, low self-esteem, sleep disorders and also aggression level."	7.73	[The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research]. ( Florkowski, A; Gałecki, P; Zboralski, K, 2005)
"Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65."	5.37	Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. ( Camargos, EF; Freitas, MP; Lima, Jde O; Medeiros-Souza, P; Miranda, LC; Pandolfi, MB; Pimentel, W; Quintas, JL, 2011)
"There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD)."	5.19	Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. ( Camargos, EF; Louzada, FM; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2014)
"Despite its frequent use as a hypnotic, trazodone has not been systematically assessed in fibromyalgia patients."	5.14	Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2010)
"From this review, it is concluded that there are very few data to suggest that trazodone improves sleep in patients without mood disorder, though it does increase total sleep in patients with major depressive disorder."	4.82	The use of trazodone as a hypnotic: a critical review. ( James, SP; Mendelson, WB, 2004)
"The evaluation of therapeutic efficiency and safety of using trazodone in treatment of adjustment disorders with the particular focus on dominant symptoms in this illness that is anxiety, lowering of the mood, low self-esteem, sleep disorders and also aggression level."	3.73	[The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research]. ( Florkowski, A; Gałecki, P; Zboralski, K, 2005)
"Melatonin intake was associated with a higher decrease in RBDSQ score compared to trazodone (P = 0."	3.11	Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. ( Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S, 2022)
"Fifty-four pregnant women with insomnia were randomly assigned to trazodone, diphenhydramine, or placebo treatment."	2.78	Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. ( Emamian, F; Ghadami, MR; Khazaie, H; Knight, DC; Tahmasian, M, 2013)
"Trazodone is a commonly prescribed off-label for sleep disturbance in alcohol-dependent patients, but its safety and efficacy for this indication is unknown."	2.73	Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. ( Friedmann, PD; Millman, RP; Rose, JS; Stein, MD; Stout, RL; Swift, R, 2008)
" Significant improvement was recorded on all items in both groups, the only significant between-group difference being in relation to how tired the patient felt during the day, which was significantly better on night-time dosage at Weeks 1 and 2."	2.65	Trazodone: alternative dose regimens and sleep. ( Wheatley, D, 1984)
"Trazodone is an antidepressant of the serotonin (5-HT2) antagonist and reuptake inhibitor class, and has been considered to act as a multifunctional drug."	2.46	[Trazodone--its multifunctional mechanism of action and clinical use]. ( Frecska, E, 2010)
" In a 9 week dosing regimen, trazodone decreased microglial NLRP3 inflammasome expression and phosphorylated p38 mitogen-activated protein kinase levels, which correlated with the NLRP3 inflammasome, the UPR effector ATF4, and total tau levels."	1.72	Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice. ( Cella, C; de Oliveira, P; Dijk, DJ; Gilmour, G; Locker, N; Mendis, A; Ravindran, KKG; Wafford, K; Winsky-Sommerer, R, 2022)
"Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65."	1.37	Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. ( Camargos, EF; Freitas, MP; Lima, Jde O; Medeiros-Souza, P; Miranda, LC; Pandolfi, MB; Pimentel, W; Quintas, JL, 2011)
"Trazodone was frequently recommended for sleep problems."	1.34	Reasons for antidepressant prescriptions in Canada. ( Carter, B; Esposito, E; Patten, SB, 2007)
"Trazodone was effective in improving sleep and decreasing rage attacks and was well tolerated, even in toddlers."	1.33	Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. ( Dukart, WS; Flint, MJ; Hoffman, MT; Oksa, AE; Pranzatelli, MR; Tate, ED, 2005)
"Fluoxetine is an effective serotonin reuptake inhibitor antidepressant that can fail to alleviate either insomnia or major depression in a substantial minority of depressed patients."	1.28	Possible trazodone potentiation of fluoxetine: a case series. ( Cole, JO; Glass, L; Nierenberg, AA, 1992)

Research

Studies (32)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Change From Baseline to 24 Weeks in ADAS-cog

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (15.63)	18.7374
1990's	2 (6.25)	18.2507
2000's	8 (25.00)	29.6817
2010's	12 (37.50)	24.3611
2020's	5 (15.63)	2.80

Authors	Studies
de Oliveira, P	1
Cella, C	1
Locker, N	1
Ravindran, KKG	1
Mendis, A	1
Wafford, K	1
Gilmour, G	1
Dijk, DJ	1
Winsky-Sommerer, R	1
Hadi, F	1
Agah, E	1
Tavanbakhsh, S	1
Mirsepassi, Z	1
Mousavi, SV	1
Talachi, N	1
Tafakhori, A	1
Aghamollaii, V	1
Schreiber, S	1
Pick, CG	1
Pereira, JA	1
Ravichandran, CT	1
Mullett, J	1
McDougle, CJ	1
Keary, CJ	1
McCleery, J	3
Sharpley, AL	3
Burke, SL	1
Hu, T	1
Spadola, CE	1
Li, T	1
Naseh, M	1
Burgess, A	1
Cadet, T	1
Khazaie, H	1
Ghadami, MR	1
Knight, DC	1
Emamian, F	1
Tahmasian, M	1
Camargos, EF	2
Louzada, LL	1
Quintas, JL	2
Naves, JO	1
Louzada, FM	1
Nóbrega, OT	1
Cohen, DA	2
Brownlow, JA	1
Harb, GC	1
Ross, RJ	1
Friedmann, PD	1
Rose, JS	1
Swift, R	1
Stout, RL	1
Millman, RP	2
Stein, MD	2
Brass, SD	1
Auerbach, S	1
Morillas-Arques, P	1
Rodriguez-Lopez, CM	1
Molina-Barea, R	1
Rico-Villademoros, F	1
Calandre, EP	1
Frecska, E	1
Pandolfi, MB	1
Freitas, MP	1
Lima, Jde O	1
Miranda, LC	1
Pimentel, W	1
Medeiros-Souza, P	1
Kurth, ME	1
Sharkey, KM	1
Anderson, BJ	1
Corso, RP	1
Shamseddeen, W	1
Clarke, G	1
Keller, MB	1
Wagner, KD	1
Birmaher, B	1
Emslie, GJ	1
Ryan, N	1
Asarnow, JR	1
Porta, G	1
Brent, DA	1
Abe, Y	1
James, SP	1
Mendelson, WB	1
Pranzatelli, MR	1
Tate, ED	1
Dukart, WS	1
Flint, MJ	1
Hoffman, MT	1
Oksa, AE	1
Gałecki, P	1
Zboralski, K	1
Florkowski, A	1
Patten, SB	1
Esposito, E	1
Carter, B	1
Klier, CM	1
Mossaheb, N	1
Saria, A	1
Schloegelhofer, M	1
Zernig, G	1
Wheatley, D	1
Montgomery, I	1
Oswald, I	1
Morgan, K	1
Adam, K	1
Zimmer, B	1
Daly, F	1
Benjamin, L	1
Balon, R	1
Nierenberg, AA	1
Cole, JO	1
Glass, L	1
Benkelfat, C	1
Gay, C	1
Renardet, M	1
Ali, CJ	1
Henry, JA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study[NCT01867775]	Phase 3	30 participants (Anticipated)	Interventional	2012-05-31	Recruiting
A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia[NCT03066518]	Phase 4	40 participants (Actual)	Interventional	2016-01-15	Completed
Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.[NCT00706186]	Phase 4	4 participants (Actual)	Interventional		Terminated (stopped due to Withdrawn by Investigator, protocol in revision)
[NCT00000171]	Phase 3	0 participants	Interventional		Completed
A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)[NCT00035204]	Phase 4	63 participants (Actual)	Interventional		Completed
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor[NCT00940589]	Phase 2	73 participants (Actual)	Interventional	2009-09-30	Completed
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects[NCT00325728]	Phase 2	74 participants (Actual)	Interventional	2006-03-21	Completed
The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients[NCT00480870]	Phase 4	65 participants (Actual)	Interventional	1999-04-30	Completed
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210]	Phase 4	2 participants (Actual)	Interventional	2008-02-29	Terminated
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study[NCT00814502]		20 participants (Actual)	Interventional	2008-12-31	Completed
Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.[NCT02267057]	Phase 4	163 participants (Actual)	Interventional	2014-08-31	Completed
Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study[NCT01142258]	Phase 3	40 participants (Actual)	Interventional	2010-03-31	Completed
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease[NCT02750306]	Phase 3	285 participants (Actual)	Interventional	2016-05-23	Completed
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild t[NCT01266525]	Phase 2	291 participants (Actual)	Interventional	2011-02-28	Completed
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled[NCT01548287]	Phase 2	164 participants (Actual)	Interventional	2012-04-30	Completed
[NCT05753943]		0 participants	Expanded Access		No longer available
Trazodone for Sleep Disturbance - Early Alcohol Recovery[NCT00027053]	Phase 2	173 participants (Actual)	Interventional	2002-06-30	Completed
Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)[NCT00791739]	Phase 4	66 participants (Actual)	Interventional	2008-04-30	Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902]	Phase 2/Phase 3	334 participants (Actual)	Interventional	2001-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a cognitive testing instrument used in clinical trials. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities that are often referred to as the core symptoms of AD. The test comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline. ADAS-cog was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Change From Baseline to 24 Weeks in iADL

Intervention	Scores on a scale (Mean)
Circadin	0.45
Placebo	0.19

Instrumental Activities of Daily Living (iADL). The scale rates activities that represent key life tasks that people need to manage. These tasks are valuable for evaluating persons with early-stage disease, both to assess the level of disease and to determine the person's ability to care for himself or herself. Scores of 0 or 1 are given to every task (Bathing, Dressing, Tolieting, transferring, Continence and Feeding) to a total score of 6. , while 0 represents a patient who is very dependent and 6 represents patient who is independent. iADL was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Change From Baseline to 24 Weeks in MMSE

Intervention	Scores on a scale (Mean)
Circadin	0.77
Placebo	1.62

The Mini Mental State Examination (MMSE) is a brief assessment instrument used to assess cognitive function in elderly patients. The MMSE can be used to screen for cognitive impairment and as a measurement of cognition over time and with pharmacologic treatment. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention: the maximum score is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures: the maximum score is 9. The scoring range for the MMSE is 0-30. Higher score represents better performance. MMSE was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Nocturnal Sleep Length at 1 Month

Sleep Efficiency

Intervention	Scores on a scale (Mean)
Circadin	-0.3
Placebo	-1.9

Intervention	hours (Median)
Modafinil	9.5

"Sleep efficiency during the down interval. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep. Sleep efficiency is calculated as (100*sleep minutes)/[time interval from sleep onset (as defined by the sleep latency) to sleep offset (the end of the last sleep episode in the Down interval)].~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: Post-intervention, up to 3 weeks

Sleep Minutes

Intervention	percentage of sleep (see above) (Least Squares Mean)
Zolpidem CR	75.93
Placebo	75.30

"Total sleep minutes during the down period. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: post-intervention, up to 3 weeks

Measures of Aggression, Psychosis, General Clinical Status, Cognitive Measures, Mood Symptoms

Intervention	sleep minutes (Least Squares Mean)
Zolpidem CR	443.71
Placebo	422.49

"Rating Scale for Aggressive Behavior in the Elderly (RAGE, 0-61); higher is worse.~Disruptive Behavior Rating Scales (DBRS, 0-105); higher is worse.~Neuropsychiatric Inventory (NPI, 0-144) - measures 12 different domains of neuropsychiatric symptoms such as delusions, hallucinations, anxiety, depression, apathy, etc.; higher is worse.~Montgomery-Asberg Depression Rating Scale (MADRS, 0-90); higher is worse.~Mini-mental state examination (MMSE, 0-30); higher is better.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the firs" (NCT00814502)
Timeframe: post-intervention, up to 3 weeks

Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4

Intervention	units on a scale (Least Squares Mean)
	NPI Total Score	RAGE Total Score	DBRS Total Score	MMSE Total Score	MADRS Total Score
Placebo	18.64	5.82	22.47	21.57	22.56
Zolpidem CR	18.00	1.40	22.64	24.45	22.96

TST was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography, during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4

Change From Baseline in Polysomnography-derived Wakefulness After Persistent Sleep Onset (WASO) at Week 4

Intervention	Minutes (Least Squares Mean)
Suvorexant	73.4
Placebo	45.2

WASO was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

Intervention	Minutes (Least Squares Mean)
Suvorexant	-45.0
Placebo	-29.4

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02750306)
Timeframe: Up to 4 weeks

Percentage of Participants Who Experienced One or More Adverse Events

Intervention	Percentage of participants (Number)
Suvorexant	0.7
Placebo	0.7

Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Percentage of participants (Number)
Suvorexant	22.5
Placebo	16.1

Change from baseline in latency of persistent sleep after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.

Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Minutes (Least Squares Mean)
AZD5213 Dose A	1.77
AZD5213 Dose B	9.84
AZD5213 Dose C	-6.85
Placebo	2.70

Intervention	Rank transformed duration (minutes) (Least Squares Mean)
AZD5213 Dose A	-2.23
AZD5213 Dose B	14.48
AZD5213 Dose C	-5.84
Placebo	-5.68

Change from baseline in night total sleep time after 4 weeks of treatment: assessed if valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Minutes (Least Squares Mean)
AZD5213 Dose A	7.07
AZD5213 Dose B	-12.42
AZD5213 Dose C	-18.97
Placebo	-7.51

Change from baseline in sleep efficiency after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.

Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.

Intervention	% (efficiency=% of time asleep) (Least Squares Mean)
AZD5213 Dose A	-0.05
AZD5213 Dose B	-3.20
AZD5213 Dose C	-1.92
Placebo	-1.83

Intervention	% change (Least Squares Mean)
AZD5213 Dose A	0.08
AZD5213 Dose B	-1.51
AZD5213 Dose C	-2.82
Placebo	0.96

Total sleep time (TST) is defined as the total time in minutes, that subjects were determined to be in a sleep state by polysomnography (PSG) measurement. (NCT01548287)
Timeframe: Baseline and Week 4.

Article	Year
Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:10 Topics: Clonazepam; Double-Blind Method; Humans; Iran; Melatonin; Parkinson Disease; Sleep Wake Disorders; T	2022
Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. Psychiatry research, 2013, Dec-30, Volume: 210, Issue:3 Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Depression; Depression, Postpartum; Dip	2013
Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2014, Volume: 22, Issue:12 Topics: Actigraphy; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Comorbidity; Double-Bli	2014
Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:9 Topics: Adult; Alcoholism; Anti-Anxiety Agents; Central Nervous System Depressants; Dose-Response Relationsh	2008
Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC musculoskeletal disorders, 2010, Sep-10, Volume: 11 Topics: Adult; Aged; Female; Fibromyalgia; Humans; Hypnotics and Sedatives; Male; Middle Aged; Selective Ser	2010
Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug and alcohol dependence, 2012, Jan-01, Volume: 120, Issue:1-3 Topics: Adult; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Methadone; Narcotics; Opi	2012
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. Journal of child and adolescent psychopharmacology, 2012, Volume: 22, Issue:1 Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450	2012
Trazodone: alternative dose regimens and sleep. Pharmatherapeutica, 1984, Volume: 3, Issue:9 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Drug Ad	1984

Article	Year
Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2022, 04-20, Volume: 42, Issue:16 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Disease Progression; Humans; Inflammasomes; Male	2022
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Medical hypotheses, 2020, Volume: 136 Topics: Analgesics; Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Disease Models, Animal;	2020
Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome. American journal of medical genetics. Part A, 2020, Volume: 182, Issue:8 Topics: Adolescent; Adult; Angelman Syndrome; Child; Child, Preschool; Clonidine; Female; Humans; Male; Mela	2020
Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications. Sleep medicine, 2018, Volume: 52 Topics: Aged; Alleles; Anti-Anxiety Agents; Apolipoprotein E4; Cognitive Dysfunction; Female; Genotype; Huma	2018
A sleepy patient with REM rebound. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009, Aug-15, Volume: 5, Issue:4 Topics: Adult; Antidepressive Agents; Depressive Disorder; Diagnosis, Differential; Humans; Male; Narcolepsy	2009
Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. Arquivos de neuro-psiquiatria, 2011, Volume: 69, Issue:1 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Dementia; Female; Humans; Hypnoti	2011
Sleep disturbances with suicidal ideation have resisted for many years: lessons from a PTSD case. Asian journal of psychiatry, 2012, Volume: 5, Issue:2 Topics: Adult; Female; Humans; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Stress Disorde	2012
Sleeping pills without regrets. They've long been the risky quick fixes of sleep medicine. Soon some sleeping pills may be sold as long-term solutions. Harvard health letter, 2004, Volume: 29, Issue:10 Topics: Acetamides; Age Factors; Azabicyclo Compounds; Benzodiazepines; Humans; Hypnotics and Sedatives; Pip	2004
Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. The Journal of pediatrics, 2005, Volume: 147, Issue:3 Topics: Adolescent; Affective Symptoms; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; H	2005
[The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 19, Issue:110 Topics: Adjustment Disorders; Adult; Affect; Aggression; Anxiety; Depression; Female; Humans; Male; Psychiat	2005
Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Canada; Databases, Factual; Depression; Hum	2007
Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Cyclohexanols; Dibenzothiazepines; Female; Human	2007
Trazodone enhances sleep in subjective quality but not in objective duration. British journal of clinical pharmacology, 1983, Volume: 16, Issue:2 Topics: Aged; Electroencephalography; Electromyography; Female; Humans; Male; Middle Aged; Piperazines; Slee	1983
More on combination antidepressant therapy. Archives of general psychiatry, 1984, Volume: 41, Issue:5 Topics: Adult; Aged; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Male; Phenelzine; Piper	1984
Sleep terror disorder and insomnia treated with trazodone: a case report. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1994, Volume: 6, Issue:3 Topics: Child; Female; Humans; Hydroxyzine; Imipramine; Sleep Initiation and Maintenance Disorders; Sleep Wa	1994
Possible trazodone potentiation of fluoxetine: a case series. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:3 Topics: Adult; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; M	1992
Use of interactive computer technology in open clinical trials. Study with trazodone in depressed patients. Neuropsychobiology, 1986, Volume: 15 Suppl 1 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Computers; Depressive Disorder; Dizziness; Female	1986
Trazodone overdosage: experience over 5 years. Neuropsychobiology, 1986, Volume: 15 Suppl 1 Topics: Adult; Child; Dizziness; Humans; Sleep Stages; Sleep Wake Disorders; Trazodone; Vomiting	1986

trazodone and Sleep Wake Disorders